BRIEF published on 09/08/2026 at 22:05, 27 days 9 hours ago Inventiva presents its advancements at the Paris MASH 2026 Congress Inventiva MASH Lanifibranor Clinical Phase PPAR
BRIEF published on 09/08/2026 at 22:05, 27 days 9 hours ago Inventiva to Showcase Lanifibranor Data at Paris MASH 2026 Clinical Data Inventiva MASH Lanifibranor PPAR Agonist
PRESS RELEASE published on 09/08/2026 at 22:00, 27 days 9 hours ago Inventiva to Present Multiple Abstracts at Paris MASH 2026 Inventiva to present Phase 1 and Phase 2 clinical data on lanifibranor at Paris MASH 2026, showing improvements in metabolic and cardiovascular factors in MASH patients. Lanifibranor's pan-PPAR pharmacology highlighted Clinical Data Inventiva Lanifibranor Metabolic Dysfunction Paris MASH 2026
BRIEF published on 09/02/2026 at 22:10, 1 month 3 days ago Inventiva Completes Final Visit of the NATiV3 Lanifibranor Study Clinical Study Phase 3 Inventiva MASH Lanifibranor
BRIEF published on 09/02/2026 at 22:10, 1 month 3 days ago Inventiva Completes Key Milestone in MASH Clinical Trial Biopharmaceutical Inventiva Lanifibranor MASH Treatment NATiV3 Trial
PRESS RELEASE published on 09/02/2026 at 22:05, 1 month 3 days ago Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH Inventiva completes last patient visit in Phase 3 trial for lanifibranor in MASH treatment, with topline results expected in Q4 2026. Financial results update scheduled for H1 2026 Phase 3 Trial Inventiva Lanifibranor MASH Treatment Financial Results Update
BRIEF published on 08/31/2026 at 22:10, 1 month 5 days ago Inventiva Appoints Chris Benecchi as Chief Operating Officer Biopharmaceutical Phase 3 Study Inventiva Lanifibranor Chris Benecchi
BRIEF published on 08/31/2026 at 22:10, 1 month 5 days ago Chris Benecchi appointed COO by Inventiva Biopharmaceutical Inventiva MASH Lanifibranor Chris Benecchi
PRESS RELEASE published on 08/31/2026 at 22:05, 1 month 5 days ago Inventiva Appoints Chris Benecchi as Chief Operating Officer Inventiva appoints Chris Benecchi as Chief Operating Officer to lead operational readiness for lanifibranor Phase 3 study results and potential commercialization, enhancing MASH treatment approach Chief Operating Officer Inventiva MASH Lanifibranor Chris Benecchi
BRIEF published on 07/29/2026 at 22:05, 2 months 7 days ago Inventiva Releases Preliminary Financial Results for H1 2026 Cash Flow Biopharmaceutical Inventiva R&D Expenses Financial Results 2026
Published on 10/05/2026 at 22:30, 9 hours 1 minute ago EV Nickel Announces Formation of Wholly Owned Subsidiary to Advance Nickel Bioleaching Technology and Canadian Nickel Supply Chain
Published on 10/05/2026 at 14:45, 16 hours 46 minutes ago NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Published on 10/05/2026 at 14:30, 17 hours 1 minute ago Hillcrest and Equipmake Expand Partnership Talks to Include Commercial Licensing of ZVS Technology
Published on 10/05/2026 at 14:30, 17 hours 1 minute ago Solitario CEO to Present at John Tumazos Very Independent Research, LLC
Published on 10/05/2026 at 14:00, 17 hours 31 minutes ago Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth
Published on 10/06/2026 at 07:00, 31 minutes ago Julius Baer Board of Directors announces two new Director nominations
Published on 10/06/2026 at 07:00, 31 minutes ago Trading Update: Continued Weak Demand and Further Inflation-Driven Cost Increases - wienerberger Adjusts Full-Year Guidance
Published on 10/06/2026 at 06:30, 1 hour ago Formycon Optimizes Biosimilar Development with AI-Powered Technologies: Digital Solutions Enhance Development Efficiency as Part of the FYB4GROWTH Strategy
Published on 10/06/2026 at 03:00, 4 hours 31 minutes ago Qupital Unveils World’s First AI-Driven On-Chain E-Commerce Lending Protocol, Accelerating Web3 Global Trade Finance
Published on 10/05/2026 at 22:12, 9 hours 18 minutes ago AXA - Elimination of the dilutive impact of Shareplan 2026
Published on 10/05/2026 at 18:13, 13 hours 18 minutes ago Disclosure of shares outstanding and voting rights - 05.10.2026
Published on 10/05/2026 at 17:45, 13 hours 46 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 10/05/2026 at 17:45, 13 hours 46 minutes ago Declaration of voting rights at the end of September 2026
